Early effects of intravitreal anti-VEGF agents on cornea and AV of DR

A total 38 eyes (30 patients) were enrolled in this study. Twenty-one eyes received conbercept, and 17 eyes received ranibizumab by intravitreal injection. Twenty eyes were classified as NPDR and 18 eyes as PDR. No significant difference were found between the groups receiving conbercept and ranibizumab in the increase in BCVA (−0.08 ± 0.06 vs. −0.05 ± 0.03 LogMAR, P = 0.60 > 0.05) nor in the increase of CCT (−1.5 ± 4.5 vs. 2.7 ± 1.2 μm, P = 0.42 > 0.05). As compared with patients with NPDR eyes, those with PDR eyes demonstrated a significantly greater increase in CCT (−5.1 ± 3.7 vs. 6.5 ± 2.8 μm, P = 0.02 < 0.05) but not in BCVA (−0.1 ± 0.04 vs. −0.03 ± 0.06 LogMAR, P = 0.33 > 0.05).